The Current State of the Osteoarthritis Drug Development Pipeline: a Comprehensive Narrative Review of the Present Challenges and Future Opportunities

Overview

Journal Ther Adv Musculoskelet Dis

Date 2022 Dec 12

PMID 36504595

Authors

Heungdeok Kim

Jinwon Seo

Yunsin Lee

Kiwon Park

Thomas A Perry

Nigel K Arden

Ali Mobasheri

Heonsik Choi

Affiliations

Soon will be listed here.

Abstract

In this narrative review article, we critically assess the current state of the osteoarthritis (OA) drug development pipeline. We discuss the current state-of-the-art in relation to the development and evaluation of candidate disease-modifying OA drugs (DMOADs) and the limitations associated with the tools and methodologies that are used to assess outcomes in OA clinical trials. We focus on the definition of DMOADs, highlight the need for an updated definition in the form of a consensus statement from all the major stakeholders, including academia, industry, regulatory agencies, and patient organizations, and provide a summary of the results of recent clinical trials of novel DMOAD candidates. We propose that DMOADs should be more appropriately targeted and investigated according to the emerging clinical phenotypes and molecular endotypes of OA. Based on the findings from recent clinical trials, we propose key topics and directions for the development of future DMOADs.

Citing Articles

Therapeutic Controlled Release Strategies for Human Osteoarthritis.

Wang D, Liu W, Venkatesan J, Madry H, Cucchiarini M Adv Healthc Mater. 2024; 14(2):e2402737.

PMID: 39506433 PMC: 11730424. DOI: 10.1002/adhm.202402737.

Mesenchymal Stem Cell-Derived Exosomes as a Treatment Option for Osteoarthritis.

Vadhan A, Gupta T, Hsu W Int J Mol Sci. 2024; 25(17).

PMID: 39273098 PMC: 11395657. DOI: 10.3390/ijms25179149.

Investigating the relationship between radiographic joint space width loss and deep learning-derived magnetic resonance imaging-based cartilage thickness loss in the medial weight-bearing region of the tibiofemoral joint.

Minnig M, Arbeeva L, Niethammer M, Nissman D, Lund J, Marron J Osteoarthr Cartil Open. 2024; 6(3):100508.

PMID: 39238657 PMC: 11375264. DOI: 10.1016/j.ocarto.2024.100508.

Advanced therapies in orthopaedics.

Winkler T, Geissler S, Maleitzke T, Perka C, Duda G, Hildebrandt A EFORT Open Rev. 2024; 9(9):837-844.

PMID: 39222330 PMC: 11457816. DOI: 10.1530/EOR-24-0084.

Tissue engineering and future directions in regenerative medicine for knee cartilage repair: a comprehensive review.

Primorac D, Molnar V, Tsoukas D, Uzieliene I, Tremolada C, Brlek P Croat Med J. 2024; 65(3):268-287.

PMID: 38868973 PMC: 11157252.

References

Chimal-Monroy J, Rodriguez-Leon J, Montero J, Ganan Y, Macias D, Merino R . Analysis of the molecular cascade responsible for mesodermal limb chondrogenesis: Sox genes and BMP signaling. Dev Biol. 2003; 257(2):292-301. DOI: 10.1016/s0012-1606(03)00066-6. View

Felson D, Niu J, Guermazi A, Sack B, Aliabadi P . Defining radiographic incidence and progression of knee osteoarthritis: suggested modifications of the Kellgren and Lawrence scale. Ann Rheum Dis. 2011; 70(11):1884-6. PMC: 3653624. DOI: 10.1136/ard.2011.155119. View

Wang S, Wei X, Zhou J, Zhang J, Li K, Chen Q . Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis. Arthritis Rheumatol. 2014; 66(7):1843-53. PMC: 4187342. DOI: 10.1002/art.38576. View

Suri S, Walsh D . Osteochondral alterations in osteoarthritis. Bone. 2011; 51(2):204-11. DOI: 10.1016/j.bone.2011.10.010. View

Fleischmann R, Bliddal H, Blanco F, Schnitzer T, Peterfy C, Chen S . A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis Rheumatol. 2019; 71(7):1056-1069. DOI: 10.1002/art.40840. View

Deshmukh V, Hu H, Barroga C, Bossard C, Kc S, Dellamary L . A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2017; 26(1):18-27. DOI: 10.1016/j.joca.2017.08.015. View

Gaffney L, Warren P, Wrona E, Fisher M, Freytes D . Macrophages' Role in Tissue Disease and Regeneration. Results Probl Cell Differ. 2017; 62:245-271. DOI: 10.1007/978-3-319-54090-0_10. View

Hochberg M, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P . Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial. JAMA. 2019; 322(14):1360-1370. PMC: 6784851. DOI: 10.1001/jama.2019.14735. View

Vincent T . Of mice and men: converging on a common molecular understanding of osteoarthritis. Lancet Rheumatol. 2020; 2(10):e633-e645. PMC: 7511206. DOI: 10.1016/S2665-9913(20)30279-4. View

10.

Badlani N, Oshima Y, Healey R, Coutts R, Amiel D . Use of bone morphogenic protein-7 as a treatment for osteoarthritis. Clin Orthop Relat Res. 2008; 467(12):3221-9. PMC: 2772903. DOI: 10.1007/s11999-008-0569-9. View

11.

Rosen J, Niazi F, Dysart S . Cost-Effectiveness of Treating Early to Moderate Stage Knee Osteoarthritis with Intra-articular Hyaluronic Acid Compared to Conservative Interventions. Adv Ther. 2019; 37(1):344-352. PMC: 6979456. DOI: 10.1007/s12325-019-01142-x. View

12.

Francis D, Hutadilok N, Kongtawelert P, Ghosh P . Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo. Rheumatol Int. 1993; 13(2):61-4. DOI: 10.1007/BF00307735. View

13.

Daheshia M, Yao J . The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol. 2008; 35(12):2306-12. DOI: 10.3899/jrheum.080346. View

14.

Oo W, Little C, Duong V, Hunter D . The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date. Drug Des Devel Ther. 2021; 15:2921-2945. PMC: 8273751. DOI: 10.2147/DDDT.S295224. View

15.

Finan P, Buenaver L, Bounds S, Hussain S, Park R, Haque U . Discordance between pain and radiographic severity in knee osteoarthritis: findings from quantitative sensory testing of central sensitization. Arthritis Rheum. 2012; 65(2):363-72. PMC: 3863776. DOI: 10.1002/art.34646. View

16.

Samuel A, Kanimozhi D . Outcome measures used in patient with knee osteoarthritis: With special importance on functional outcome measures. Int J Health Sci (Qassim). 2019; 13(1):52-60. PMC: 6392485. View

17.

Li Q, Amano K, Link T, Ma C . Advanced Imaging in Osteoarthritis. Sports Health. 2016; 8(5):418-28. PMC: 5010138. DOI: 10.1177/1941738116663922. View

18.

Tayton E, Frampton C, Hooper G, Young S . The impact of patient and surgical factors on the rate of infection after primary total knee arthroplasty: an analysis of 64,566 joints from the New Zealand Joint Registry. Bone Joint J. 2016; 98-B(3):334-40. DOI: 10.1302/0301-620X.98B3.36775. View

19.

Lohmander L, Hellot S, Dreher D, Krantz E, Kruger D, Guermazi A . Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014; 66(7):1820-31. DOI: 10.1002/art.38614. View

20.

Van Manen M, Nace J, Mont M . Management of primary knee osteoarthritis and indications for total knee arthroplasty for general practitioners. J Am Osteopath Assoc. 2012; 112(11):709-15. View